Search
Learn about how cognitive behavioral therapy for insomnia (CBT-I) helps people with cancer improve sleep.
Learn about a new vaccine at MSK that could prevent neuroblastoma from returning after treatment.
Developed by scientists at MSK and the University of British Columbia/BC Cancer, the platform provides the deepest look yet into tumor evolution.
A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences welcomed its ninth class of PhD students on July 21, 2014.
MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.
Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.
Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.
New MSK research develops a new tool for studying mitochondrial DNA deletions; uncovers mechanisms of histiocytosis-associated neurodegeneration; and investigates how mutant stem cells co-opt regeneration to make tumors grow.
Recently, dozens of survivors, their parents, and members of the Memorial Sloan Kettering Cancer Center (MSK) Department of Pediatrics joined the Times Square Advertising Coalition to turn the bright lights of Times Square gold to raise awareness for pediatric cancer.